Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic arthritis/PsA who had not previously received a biologic disease-modifying antirheumatic drug/bDMARD.

The company also announced new findings from an integrated analysis of the Phase 2 PAISLEY-SLE and PAISLEY long-term extension/LTE studies. The results showed sustained safety and efficacy with up to four years of Sotyktu treatment for patients with moderate-to-severe systemic lupus erythematosus/SLE.

Sotyktu is an oral, selective tyrosine kinase 2/TYK2 inhibitor that represents a new class of small molecules. It achieves its effect by selectively binding to the regulatory domain of TYK2, leading to the allosteric inhibition of TYK2 and its downstream functions involving key cytokines. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2, or JAK3. The drug is already approved in numerous countries globally for the treatment of adults with moderate-to-severe plaque psoriasis.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.